 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...171172173174175176177178179180181...235236» |
- | New P3 trial, Metastases: GEMPAX: Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - May 8, 2019
P3, N=210, Not yet recruiting, Sponsor: UNICANCER
- | Datalai (cetuximab biosimilar) / Sichuan Kelun Pharma
New P3 trial: KL140-III-01: Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial (clinicaltrials.gov) - May 8, 2019
P3, N=570, Recruiting, Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
- | leucovorin calcium / generics, methotrexate / generics
Clinical, Journal: Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. (Pubmed Central) - May 8, 2019
It is safe to administer 3 or 5 gm/m of MTX (24 hr infusion) without measuring MTX levels, with extended hydration, additional doses of leucovorin, and monitoring of serum creatinine and urine pH.
- || CYAD-01 / Celdara Medical, Celyad Oncology
Enrollment closed: Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases (clinicaltrials.gov) - May 8, 2019
P1, N=36, Active, not recruiting, Sponsor: Celyad (formerly named Cardio3 BioSciences)
It is safe to administer 3 or 5 gm/m of MTX (24 hr infusion) without measuring MTX levels, with extended hydration, additional doses of leucovorin, and monitoring of serum creatinine and urine pH. Recruiting --> Active, not recruiting
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Synergic and comparative effect of 5-fluorouracil and leucoverin on breast and colon cancer cells through TRPM2 channels. (Pubmed Central) - May 7, 2019
6, Ref. 43).
- | oxaliplatin / generics, leucovorin calcium / generics, fluorouracil / generics
Retrospective data, Journal: Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. (Pubmed Central) - May 7, 2019
43). HAIC is a potential treatment option for advanced HCC with limited extrahepatic metastases in a population with hepatitis B virus infection.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: A case of an elderly patient with high-grade colorectal cancer in poor general condition who showed near complete response to chemotherapy and achieved long-term survival. (Pubmed Central) - May 7, 2019
HAIC is a potential treatment option for advanced HCC with limited extrahepatic metastases in a population with hepatitis B virus infection. Although the use of chemotherapy for elderly with advanced unresectable colorectal cancer or those with poor PS is limited, this case shows that systemic chemotherapy is now an option for such cases previously managed with BSC.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: HNGC-004: Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma (clinicaltrials.gov) - May 7, 2019
P2, N=60, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
New trial: Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders (clinicaltrials.gov) - May 6, 2019
P=N/A, N=15, Recruiting, Sponsor: Ascension South East Michigan
- |||||||||| pamrevlumab (FG-3019) / FibroGen
New P3 trial, Combination therapy, Metastases: LAPIS: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer (clinicaltrials.gov) - May 6, 2019
P3, N=256, Not yet recruiting, Sponsor: FibroGen
- | Otrexup (methotrexate) / Assertio, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - May 6, 2019
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Although the use of chemotherapy for elderly with advanced unresectable colorectal cancer or those with poor PS is limited, this case shows that systemic chemotherapy is now an option for such cases previously managed with BSC. Trial primary completion date: Jul 2019 --> Jul 2020
- | Trial completion date, Metastases: S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer (clinicaltrials.gov) - May 6, 2019
P2, N=213, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Jul 2019 --> Jul 2020 Trial completion date: Mar 2019 --> Sep 2019
- ||| andecaliximab (GS-5745) / Gilead
Trial completion, Combination therapy, Monotherapy, Metastases: Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2019
P1, N=236, Completed, Sponsor: Gilead Sciences
Trial completion date: Mar 2019 --> Sep 2019 Active, not recruiting --> Completed
- | leucovorin calcium / generics, fluorouracil / generics
Biomarker, Preclinical, Journal: Thymidine Metabolism as Confounding Factor of 3'-Deoxy-3'-[F]Fluorothymidine Uptake after Therapy in a Colorectal Cancer Model. (Pubmed Central) - May 5, 2019
As tracer uptake was unaltered in the HCT116 model, these changes appear to be specific for tumor response.We demonstrate that [F]FLT PET can non-invasively monitor molecular alterations induced by a cancer treatment, including thymidine metabolism and DDR. The cellular or imaging changes may not, however, be directly related to therapy response as assessed by volumetric measurements.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Journal: Selecting chemotherapy for pancreatic cancer: Far away or so close? (Pubmed Central) - May 5, 2019
Regardless of the possible bias and exact treatment selection process, this study offers an opportunity to improve patient outcomes by using agents currently used in the therapy of pancreatic cancer. Although these conclusions are based on indirect evidence, we provide insights and possibilities to drive the selection of chemotherapy for pancreatic cancer.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. (Pubmed Central) - May 2, 2019
• In colorectal cancer, increased attenuation of liver metastases in baseline computed tomography is a prognostic factor for prolonged OS (p < 0.001). • A threshold of ≥61.62 HU was determined as optimal cut-off to identify patients with prolonged OS (p < 0.001), early tumour shrinkage (p = 0.002) and increased depth of response (p = 0.012).
- | Trial completion date: A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients (clinicaltrials.gov) - May 1, 2019
P2, N=25, Active, not recruiting, Sponsor: University of Michigan Rogel Cancer Center
• A threshold of ≥61.62 HU was determined as optimal cut-off to identify patients with prolonged OS (p < 0.001), early tumour shrinkage (p = 0.002) and increased depth of response (p = 0.012). Trial completion date: Feb 2019 --> Aug 2019
- | 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 1, 2019
P2, N=50, Completed, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Feb 2019 --> Aug 2019 Active, not recruiting --> Completed
- | Enrollment open, Trial initiation date, Metastases: CANWATCH: Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis (clinicaltrials.gov) - Apr 30, 2019
P=N/A, N=650, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jan 2019 --> Apr 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer (clinicaltrials.gov) - Apr 29, 2019
P3, N=560, Recruiting, Sponsor: Kyungpook National University
Not yet recruiting --> Recruiting | Initiation date: Jan 2019 --> Apr 2019 Not yet recruiting --> Recruiting
- |||| Ziihera (zanidatamab-hrii) / Jazz
New P2 trial: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2019
P2, N=91, Recruiting, Sponsor: Zymeworks Inc.
- | leucovorin calcium / generics
Journal: 5,10-methenyltetrahydrofolate synthetase deficiency causes a neurometabolic disorder associated with microcephaly, epilepsy, and cerebral hypomyelination. (Pubmed Central) - Apr 28, 2019
...The first patient was treated with folinic acid, which resulted in worsening cerebral folate deficiency...Measurement of MTHFS enzyme activity in fibroblasts confirmed reduced activity. The direct substrate of the MTHFS reaction, 5-formyl-THF, was elevated 30-fold in patient fibroblasts compared to control, supporting the hypothesis that the pathophysiology of this disorder is a manifestation of toxicity from this metabolite.
- | Avastin (bevacizumab) / Roche
Clinical, P2 data, Retrospective data, Journal: Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer Aged at Least 75 Years: A Post-Hoc Subgroup Analysis of Three Phase II Trials. (Pubmed Central) - Apr 27, 2019
In one study, bevacizumab was also added to chemotherapy...Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR: Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. (Pubmed Central) - Apr 26, 2019
It did not affect HRQL and showed similar rates of treatment-emergent adverse events as those observed in the VELOUR trial. No new safety signals were identified.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Retrospective data, Journal: Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. (Pubmed Central) - Apr 26, 2019
No new safety signals were identified. The results of the present meta-analysis with a combined sample size of 1461 patients suggest that it is reasonable to consider mFIO regimens for patients with metastatic pancreatic adenocarcinoma.
- | Avastin (bevacizumab) / Roche
Biomarker, Clinical, Journal: Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. (Pubmed Central) - Apr 26, 2019
The results of the present meta-analysis with a combined sample size of 1461 patients suggest that it is reasonable to consider mFIO regimens for patients with metastatic pancreatic adenocarcinoma. ACVRL1 expression could serve as a prognostic biomarker in metastatic colorectal cancer patients receiving chemotherapy and bevacizumab and warrants further evaluation in prospective studies.
- | Avastin (bevacizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Clinical, P2 data, Journal: A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. (Pubmed Central) - Apr 26, 2019
Decreased treatment intensity with standard agents likely contributed to the lack of benefit with pelareorep. Future studies might consider alternate pelareorep/chemotherapy strategies or combination therapy with novel agents.
- | Stivarga (regorafenib) / Bayer
Trial completion date, Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Apr 25, 2019
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Future studies might consider alternate pelareorep/chemotherapy strategies or combination therapy with novel agents. Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Surgery, Metastases: Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 25, 2019
P1, N=8, Active, not recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Jul 2019 --> Jul 2020 Trial completion date: Jan 2019 --> Oct 2019
- || Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 24, 2019
P2, N=78, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Jan 2019 --> Oct 2019 Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- | leucovorin calcium / generics, tegafur/uracil / generics, irinotecan / generics
P1/2 data, Journal: Phase I/II Study of Preoperative Chemoradiotherapy With TEGAFIRI for Locally Advanced Rectal Cancer. (Pubmed Central) - Apr 24, 2019
TEGAFIRI is a promising CRT regimen that results in marked tumor regression and good local control. Moreover, its adverse events are well-tolerated.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. (Pubmed Central) - Apr 24, 2019
Previous bevacizumab use had no effect on the activity of subsequent EGFRIs. The apparent effect of time between biologic agents in right-sided tumors might reflect patient selection.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Biomarker, Clinical, Journal: Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer. (Pubmed Central) - Apr 23, 2019
The apparent effect of time between biologic agents in right-sided tumors might reflect patient selection. Reduced membranous expression of E-cadherin and increased cytoplasmic E-cadherin expression predict poor survival in mCRC.
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (clinicaltrials.gov) - Apr 22, 2019
P1, N=17, Completed, Sponsor: University of Chicago
Reduced membranous expression of E-cadherin and increased cytoplasmic E-cadherin expression predict poor survival in mCRC. Active, not recruiting --> Completed | N=45 --> 17
- | 5-fluorouracil / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer (clinicaltrials.gov) - Apr 20, 2019
P2, N=248, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | N=45 --> 17 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change, Metastases: MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 20, 2019
P2, N=5, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed | N=120 --> 5
- |||||| simtuzumab (GS 6624) / Gilead
Trial termination, Metastases: Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma (clinicaltrials.gov) - Apr 20, 2019
P2, N=266, Terminated, Sponsor: Gilead Sciences
Recruiting --> Completed | N=120 --> 5 Completed --> Terminated
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer (clinicaltrials.gov) - Apr 20, 2019
P2, N=56, Active, not recruiting, Sponsor: John Hays
Completed --> Terminated Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Apr 20, 2019
P2, N=240, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- ||||||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: VISNU-1: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (clinicaltrials.gov) - Apr 20, 2019
P3, N=350, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis (clinicaltrials.gov) - Apr 20, 2019
P2, N=220, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial completion date: Mar 2019 --> Sep 2020 | Trial primary completion date: Mar 2019 --> Sep 2020
- ||| Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab (clinicaltrials.gov) - Apr 20, 2019
P2, N=16, Active, not recruiting, Sponsor: John Hays
Trial completion date: Mar 2019 --> Sep 2020 | Trial primary completion date: Mar 2019 --> Sep 2020 Recruiting --> Active, not recruiting | N=35 --> 16 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- || pegilodecakin (LY3500518) / Eli Lilly
Trial primary completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2019
P1, N=350, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=35 --> 16 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Feb 2020 --> Feb 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Trial primary completion date: BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Apr 20, 2019
P2, N=38, Active, not recruiting, Sponsor: howard safran
Trial primary completion date: Feb 2020 --> Feb 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2019 --> Jun 2019
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 19, 2019
P3, N=1400, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2019 --> Jun 2019 Trial primary completion date: Dec 2023 --> Mar 2020
- || napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Apr 19, 2019
P1, N=139, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Trial primary completion date: Dec 2023 --> Mar 2020 Trial primary completion date: Mar 2019 --> Mar 2020
- ||| leucovorin calcium / generics
Clinical: We compound in-house so immediately available when needed. We connect patients with a compounding pharmacy to get outpatient supply (compounded with leucovorin), process started inpatient to ensure continuity. (Twitter) - Apr 19, 2019
- | Erbitux (cetuximab) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: ERMES: Erbitux MEtastatic Colorectal Cancer Strategy Study (clinicaltrials.gov) - Apr 19, 2019
P3, N=600, Recruiting, Sponsor: Armando Orlandi
Trial primary completion date: Mar 2019 --> Mar 2020 Trial completion date: Feb 2019 --> Aug 2020 | Trial primary completion date: Nov 2018 --> Dec 2019
- || Opdivo (nivolumab) / BMS
New P2 trial: CA209-8M4: Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients (clinicaltrials.gov) - Apr 18, 2019
P2, N=29, Recruiting, Sponsor: Baruch Brenner
- | Retrospective data, Journal: Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. (Pubmed Central) - Apr 18, 2019
Trial completion date: Feb 2019 --> Aug 2020 | Trial primary completion date: Nov 2018 --> Dec 2019 CT2 in advanced PDAC appears feasible in the Indian setting if the patients are appropriately selected and they can be treated with acceptable toxicities and reasonable outcomes.